Polyrizon Ltd.

RAANANA, L3 · CIK 0001893645 · Biotech · Private

Intranasal drug delivery platform and formulations

polyrizon-biotech.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$7.5M
2 Form D · Sep 2026
1 months since last filing
Contracts
—
No federal contracts on record
Patents
5
0 granted · 5 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$3,499,992
Private capital raisedForm D · SEC$3,999,996
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3376UNCO THERAPEUTICS LLC——
3377Inspira Therapeutics, Inc——
3378SYGNAMAP, INC.——
3379Polyrizon Ltd.—$7.5M
3380BlossomHill Therapeutics—$246M
3381Shattuck Labs, Inc.—$164M
3382Colossal Biosciences—$150M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 9 related persons
  • Oz AdlerDirector
  • Liron CarmelDirector
  • Asaf ItzhaikDirector
  • Tomer IzraeliDirector · Executive Officer
  • Eyal RonExecutive Officer
  • Liat SidiDirector
  • Tidhar TurgemanExecutive Officer
  • Yehonatan VinokurDirector
  • Nir YosefExecutive Officer

Patents

USPTO · 0 granted of 5
  • MUCOADHESlVE POLYMERS FOR NASAL DRUG DELIVERYapplication
  • Method For Removal Of Toxins From Mucosal Membranesapplication
  • Mucoadhesive Polymers For Nasal Drug Deliveryapplication
  • Mucoadhesive Polymers For Nasal Drug Deliveryapplication
  • Mucoadhesive Polymers For Nasal Drug Deliveryapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.